has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Granules India
to report net profit at Rs 52.2 crore, up 34 percent quarter-on-quarter.
Net Sales are expected to increase by 16.2 percent Q-o-Q (up 9 percent Y-o-Y) to Rs 399.3 crore, according to Centrum.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 20.6 percent Q-o-Q (up 21.2 percent Y-o-Y) to Rs 83.5 crore.
Centrum's report on Granules India
We expect Granules India’s (GIL) revenues to grow by 9% YoY and 16% QoQ to Rs3.99bn. The sales composition would be as follows: API 32%, PFI 30% and finished dosages 38%.
We expect the future growth to be driven by approval of Ibuprofen tablets of strengths 400mg, 600mg and 800mg from the US FDA and marketing of Omeprazole and sodium bicarbonate OTC capsules in the US market. GIL is among top pharma picks.Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.